Extended-cycle oral contraceptive pills with 10 μg ethinyl estradiol pills in place of placebo pills

Women's Health

Volumn 3, Issue 5, 2007, Pages 529-535

  Nelson, Anita L ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Extended cycle oral contraceptives; Hormone free interval

Indexed keywords

ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETONOGESTREL; FOLLITROPIN; GESTAGEN; INHIBIN B; LEVONORGESTREL; LONG ACTING DRUG; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; MESTRANOL PLUS NORETYNODREL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; ORTHO NOVUM 1 35; PLACEBO; SEASONIQUE; UNCLASSIFIED DRUG;

ACNE; BIRTH CONTROL; BREAST TENDERNESS; CHLOASMA; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG INDICATION; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ESTRADIOL BLOOD LEVEL; FLUID RETENTION; FOLLITROPIN BLOOD LEVEL; HORMONE RESPONSE; HUMAN; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MIGRAINE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVULATION INHIBITION; PANCREATITIS; PREMENSTRUAL SYNDROME; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SPOTTING; VAGINA BLEEDING; VIRILIZATION; WEIGHT GAIN; WITHDRAWAL BLEEDING; WITHDRAWAL SYNDROME;

EID: 35848935245     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.5.529     Document Type: Review

References (25)

1. Mishell DR Jr: Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 71(4), 304-305 (2005).
2. Andrews WC, Larsen GD: Endometriosis: treatment with hormonal pseudopregnancy and-or operation. Am. J. Obstet. Gynecol. 118(5), 643-651 (1974).
3. Hammond CB, Rock JA, Parker RT: Conservative treatment of endometriosis: the effects of limited surgery and hormonal pseudopregnancy. Fertil. Steril. 27(7), 756-766 (1976).
4. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG: A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil. Steril. 60(1), 75-79 (1993).
5. Cote I, Jacobs P, Cumming D: Work loss associated with increased menstrual loss in the United States. Obstet. Gynecol. 100(4), 683-687 (2002).
6. Coffee AL, Kuehl TJ, Willis S, Sulak PJ: Oral cbntraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am. J. Obstet. Gynecol. 195(5), 1311-1319 (2006).
7. Anderson FD, Halt H: A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68(2), 89-96 (2003).
8. Coutinho EM, Segal SJ: In: Is Menstruation Obsolete? Oxford University Press, NY, USA (1999).
9. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ: Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95(2), 261-266 (2000)
10. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL: Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am. J. Obstet. Gynecol. 186(6), 1142-1149 (2002).
11. Miller L, Notter KM: Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet. Gynecol. 98(5 Pt 1), 771-718 (2001).
12. Ferrero S, Abbamonte LH, Giordano M et al.: What is the desired menstrual frequency of women without menstruation- related symptoms? Contraception 73(5), 537-541(2006).
13. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA: Continuous or extended-cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst. Rev. (3), CD004695 (2005).
14. den Tonkelaar I, Oddens BJ: Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 59(6), 357-362 (1999).
15. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ: Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74(2), 100-103 (2006).
16. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL: Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am. J. Obstet. Gynecol. 190(4), 943-951 (2004).
17. Spona J, Elstein M, Feichtinger W et al.: Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54(2), 71-77 (1996).
18. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D: Yasmin Extended Regimen Study Group: The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception. 73(1), 34-40 (2006).
19. Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ: Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet. Gynecol. 105(6), 1389-1396 (2005).
20. Miller L, Verhoeven CH, Hout J: Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet. Gynecol. 106(3), 473-482 (2005).
21. Sulak PJ, Kuehl TJ, Coffee A, Vandeveer M, Reape KZ: Evaluation of pituitary-ovarian aids suppression with three different oral contraceptive regimens Obstet. Gynecol. 109(Suppl. 4), S102 (2007).
22. Anderson FD, Gibbons W, Portman D: Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73(3), 229-234 (2006).
23. Seasonique® Prescribing Information: Duramed Pharmaceuticals, Inc., NY, USA (2006)
24. Reape KZ, Feldman R, Anderson FD: Endometrial effects of an extended-regimen oral contraceptive with continuous low-dose estrogen. Obstet. Gynecol. 109(Suppl. 4), S13(2007).
25. Reape KZ, DiLiberti CE: Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen. Obstet. Gynecol. 109(4), S13 (2007).